382 related articles for article (PubMed ID: 22655525)
1. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
Cheetham PJ; Petrylak DP
Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
[TBL] [Abstract][Full Text] [Related]
2. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.
Liepe K
Curr Opin Investig Drugs; 2009 Dec; 10(12):1346-58. PubMed ID: 19943206
[TBL] [Abstract][Full Text] [Related]
3. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Bruland ØS; Nilsson S; Fisher DR; Larsen RH
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6250s-6257s. PubMed ID: 17062709
[TBL] [Abstract][Full Text] [Related]
4. Radium-223: down to the bone, and less is more.
Chang AJ; Roach M
Oncology (Williston Park); 2012 Apr; 26(4):342, 344. PubMed ID: 22655526
[No Abstract] [Full Text] [Related]
5. [Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].
Bertolaso P; Leroy L; Gross-Goupil M; Aupee O; Ravaud A; Roubaud G; Cazeau AL; Le Moulec S
Bull Cancer; 2017 Sep; 104(9):762-770. PubMed ID: 28797482
[TBL] [Abstract][Full Text] [Related]
6. An alpha edge?
Silberstein EB
Oncology (Williston Park); 2012 Apr; 26(4):345, 348. PubMed ID: 22655527
[No Abstract] [Full Text] [Related]
7. Radium-223 for the treatment of prostate cancer.
Hafeez S; Parker C
Expert Opin Investig Drugs; 2013 Mar; 22(3):379-87. PubMed ID: 23316941
[TBL] [Abstract][Full Text] [Related]
8. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
9. Radiation-based approaches for therapy and palliation of advanced prostate cancer.
Lewis B; Sartor O
Curr Opin Urol; 2012 May; 22(3):183-9. PubMed ID: 22453334
[TBL] [Abstract][Full Text] [Related]
10. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 Therapy of Bone Metastases in Prostate Cancer.
Nilsson S
Semin Nucl Med; 2016 Nov; 46(6):544-556. PubMed ID: 27825434
[TBL] [Abstract][Full Text] [Related]
12. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
13. Bone-targeting radiopharmaceuticals including radium-223.
Brady D; Parker CC; O'Sullivan JM
Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
[TBL] [Abstract][Full Text] [Related]
15. Radionuclide therapy for osseous metastases in prostate cancer.
Abi-Ghanem AS; McGrath MA; Jacene HA
Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
[TBL] [Abstract][Full Text] [Related]
16. Radiation for bone metastases.
Bourgeois DJ; Kraus S; Maaloof BN; Sartor O
Curr Opin Support Palliat Care; 2011 Sep; 5(3):227-32. PubMed ID: 21734581
[TBL] [Abstract][Full Text] [Related]
17. Targeted α Therapies for the Treatment of Bone Metastases.
Zustovich F; Barsanti R
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283383
[TBL] [Abstract][Full Text] [Related]
18. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
Nilsson S; Strang P; Aksnes AK; Franzèn L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland ØS
Eur J Cancer; 2012 Mar; 48(5):678-86. PubMed ID: 22341993
[TBL] [Abstract][Full Text] [Related]
19. Progress in the treatment of bone metastases in cancer patients.
Mackiewicz-Wysocka M; Pankowska M; Wysocki PJ
Expert Opin Investig Drugs; 2012 Jun; 21(6):785-95. PubMed ID: 22500564
[TBL] [Abstract][Full Text] [Related]
20. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]